Clinical and cytogenetic features of CLL families
Individual . | Sex . | Age at diagnosis, y . | Diagnosis . | WBC count, × 109/L . | Stage . | Survival status and age, y . | Flow cytometry . | Cytogenetic interphase FISH . |
---|---|---|---|---|---|---|---|---|
1-1001 | F | 47 | CLL | 112 | Rai 3 | Dead, 76 | CD5+ CLL | del 13q14 |
1-1003 | M | 52 | CLL | 59.6 | Rai 1 | Dead, 66 | np | np |
1-1005 | M | 47 | CLL | 144.6 | Rai 1 | Dead, 61 | np | np |
1-1008 | F | 58 | CLL | 32.2 | Rai 0 | Dead, 86 | np | no del 13q14 |
2-2002 | F | 69 | CLL | 17.8 | Rai 0 | Living, 80 | CD5+ CLL | del 13q14 |
2-1001 | M | 45 | CLL | 186.8 | Rai 4 | Dead, 49 | CD5+ CLL | del 13q14 |
2-1002 | M | 50 | CLL | 251 | Rai 2 | Dead, 54 | CD5+ CLL | del 13q14 |
2-1003 | F | 53 | Asymptomatic | 6.41 | NA | Living, 60 | CD5+ MBL | np |
2-1006 | F | 39 | Asymptomatic | 6.16 | NA | Living, 45 | CD5+ MBL | del 13q14 |
3-2001 | M | 76 | CLL | 12.6 | Rai 0 | Dead, 82 | CD5+ CLL | np |
3-1001 | M | 49 | CLL | 68.0 | Rai 0 | Living, 59 | CD5+ CLL | del 13q14 |
4-1001 | F | 47 | CLL | 98.4 | Rai 0 | Living, 82 | CD5+ CLL | np |
4-1002 | F | 70 | CLL | 24.6 | Rai 0 | Living, 81 | CD5+ CLL | np |
4-1003 | M | 68 | CLL | 52.1 | Rai 2 | Living, 76 | CD5+ CLL | np |
5-1002 | M | 62 | CLL | 63 | Rai 4 | Dead, 71 | CD5+ CLL | no del 13q14 |
5-1003 | M | 47 | CLL | 64 | Rai 0 | Living, 61 | CD5+ CLL | del 13q14 |
5-1005 | F | 58 | CLL | 56.7 | Rai 0 | Living, 69 | CD5+ CLL | del 13q14 |
5-1007 | M | 73 | CLL | 27.1 | Rai 4 | Living, 81 | CD5+ CLL | del 13q14 |
6-2003 | M | 59 | CLL | 20.9 | Rai 0 | Living, 64 | np | del 13q14 |
6-2012 | F | 51 | CLL | 35.9 | Rai 2 | Living, 55 | CD5+ CLL | del 13q14 |
6-1001 | F | 38 | CLL | 26.1 | Rai 0 | Living, 42 | np | del 13q14 |
Individual . | Sex . | Age at diagnosis, y . | Diagnosis . | WBC count, × 109/L . | Stage . | Survival status and age, y . | Flow cytometry . | Cytogenetic interphase FISH . |
---|---|---|---|---|---|---|---|---|
1-1001 | F | 47 | CLL | 112 | Rai 3 | Dead, 76 | CD5+ CLL | del 13q14 |
1-1003 | M | 52 | CLL | 59.6 | Rai 1 | Dead, 66 | np | np |
1-1005 | M | 47 | CLL | 144.6 | Rai 1 | Dead, 61 | np | np |
1-1008 | F | 58 | CLL | 32.2 | Rai 0 | Dead, 86 | np | no del 13q14 |
2-2002 | F | 69 | CLL | 17.8 | Rai 0 | Living, 80 | CD5+ CLL | del 13q14 |
2-1001 | M | 45 | CLL | 186.8 | Rai 4 | Dead, 49 | CD5+ CLL | del 13q14 |
2-1002 | M | 50 | CLL | 251 | Rai 2 | Dead, 54 | CD5+ CLL | del 13q14 |
2-1003 | F | 53 | Asymptomatic | 6.41 | NA | Living, 60 | CD5+ MBL | np |
2-1006 | F | 39 | Asymptomatic | 6.16 | NA | Living, 45 | CD5+ MBL | del 13q14 |
3-2001 | M | 76 | CLL | 12.6 | Rai 0 | Dead, 82 | CD5+ CLL | np |
3-1001 | M | 49 | CLL | 68.0 | Rai 0 | Living, 59 | CD5+ CLL | del 13q14 |
4-1001 | F | 47 | CLL | 98.4 | Rai 0 | Living, 82 | CD5+ CLL | np |
4-1002 | F | 70 | CLL | 24.6 | Rai 0 | Living, 81 | CD5+ CLL | np |
4-1003 | M | 68 | CLL | 52.1 | Rai 2 | Living, 76 | CD5+ CLL | np |
5-1002 | M | 62 | CLL | 63 | Rai 4 | Dead, 71 | CD5+ CLL | no del 13q14 |
5-1003 | M | 47 | CLL | 64 | Rai 0 | Living, 61 | CD5+ CLL | del 13q14 |
5-1005 | F | 58 | CLL | 56.7 | Rai 0 | Living, 69 | CD5+ CLL | del 13q14 |
5-1007 | M | 73 | CLL | 27.1 | Rai 4 | Living, 81 | CD5+ CLL | del 13q14 |
6-2003 | M | 59 | CLL | 20.9 | Rai 0 | Living, 64 | np | del 13q14 |
6-2012 | F | 51 | CLL | 35.9 | Rai 2 | Living, 55 | CD5+ CLL | del 13q14 |
6-1001 | F | 38 | CLL | 26.1 | Rai 0 | Living, 42 | np | del 13q14 |
CLL indicates chronic lymphocytic leukemia; np, not performed; NA, not applicable; and MBL, monoclonal B-cell lymphocytosis.